Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency 2/10/2021 12/31/2021 Temporary Policy for Manufacture of Alcohol for Incorporation Into Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry 3/24/2020 12/31/2021 Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) 3/19/2020 12/31/2021 Enforcement Policy – OTC Sunscreens Drug Products Marketed Without an Approved Application 5/23/2018 9/24/2021 Safety Assessment for IND Safety Reporting Guidance for Industry 12/17/2015 6/25/2021 Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Guidance for Industry 12/26/2017 5/11/2021 Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products 6/01/2015 5/11/2021 Direct-to-Consumer Television Advertisements--FDAAA DTC Television Ad Pre-Dissemination Review Program 6/1/2000 2/25/2020 Waivers of the Single, Shared System REMS Requirement; Draft Guidance for Industry 6/1/2028 2/25/2021 Content and Format for Geriatric Labeling 10/05/2001 9/15/2020 Classifying Significant Postmarketing drug safety issues 3/01/2012 4/20/2020 Immunotoxicology Evaluation of Investigational New Drugs 11/01/2002 2/19/2020 Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes 12/1/2008 3/9/2020 Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention 3/1/2008 3/9/2020 Target Product Profile -- A Strategic Development Process Tool 3/30/2007 12/13/2019 Qualification Process for Drug Development Tools 1/6/2014 12/13/2019 Acceptance of Foreign Clinical Studies 3/01/2001 12/06/2019 CPG Sec. 400.400 Conditions Under Which Homeopathic Drugs May be Marketed 3/01/1995 10/24/2019 Analgesic Indications: Developing Drugs and Biological Products 2/14/2014 08/23/2019 Guidelines for the Clinical Evaluation of Hypnotic Drugs 9/01/1997 08/23/2019 Providing Regulatory Submissions in Electronic Format—Submission of Manufacturing Establishment Information 12/29/2016 07/22/2019 Analgesic Indications: Developing Drug and Biological Products 02/05/2014 06/20/2019 Establishing Pregnancy Exposure Registries 08/01/2002 05/08/2019 In-Vivo Bioequivalence Studies Based on Population and Individual Bioequivalence Studies 12/30/1997 06/10/1999  Attachment D – Application, Product, and Establishment Fees:  Common Issues and Their Resolution 12/16/1994 11/08/2017 New Drug Evaluation Guidance Document: Refusal to File 07/12/1993 05/19/2017 Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products; Availability 02/26/1999 02/03/2000 Female Sexual Dysfunction: Clinical Development of Drug Products for Treatment 05/16/2000 07/28/2010 Part 11, Electronic Records; Electronic Signatures, Electronic Copies of Electronic Records 11/12/2002 02/04/2003 Guideline for the Clinical Evaluation of Analgesic Drugs 12/01/1992 08/05/2003 Q1F: Stability Data Package for Registration Applications for Climactic Zones III and IV 06/14/2002 11/21/2003 Clinical Evaluation of Antacid Drugs 04/01/1978 07/20/2004 Clinical Evaluation of Antidiarrheal Drugs 09/01/1977 07/20/2004 Clinical Evaluation of Gastric Secretory Depressant (GSD) Drugs 09/01/1977 07/20/2004 Clinical Evaluation of Laxative Drugs 04/01/1978 07/20/2004 Clinical Evaluation of Radiopharmaceutical Drugs 10/01/1981 07/20/2004 FDA Requirements for Approval for Drugs to Treat Superficial Bladder Cancer 06/01/1989 07/20/2004 Clozapine Tablets: In Vivo Bioequivalence and In Vitro Dissolution Testing 12/30/2003 04/01/2011 Preclinical Development of Antiviral Drugs 11/01/1990 07/06/2005 Preclinical Development of Immunomodulatory Drugs for Treatment of HIV Infection and Associated Disorders 09/04/1992 12/29/2005 Conjugated Estrogens, USP: LC-MS Method for Both Qualitative Chemical Characterization and Documentation of Qualitative Pharmaceutical Equivalence 03/09/2000 08/12/2005 Organization of an Abbreviated New Drug Application 03/02/1999 11/18/2005 BACPAC I: Intermediates in Drug Substance Synthesis; Bulk Actives Postapproval Changes:  Chemistry, Manufacturing, and Controls Information 02/01/2001 06/01/2006 Drug Product: Chemistry, Manufacturing, and Controls Information 01/01/2003 06/01/2006 Drug Substance: Chemistry, Manufacturing, and Controls Information 01/01/2004 06/01/2006 Format and Content of the Chemistry, Manufacturing, and Controls Section of an Application 02/01/1987 06/01/2006 Stability Testing of Drug Substances and Drug Products 06/01/1998 06/01/2006 Submission of Chemistry, Manufacturing, and Controls Information for Synthetic Peptides 11/01/1994 06/01/2006 Submitting Documentation for the Stability of Human Drugs and Biologics 02/01/1987 06/01/2006 Providing Electronic Submissions in Electronic Format - ANDAs 06/27/2002 09/29/2006 Providing Electronic Submissions in Electronic Format - NDAs 01/28/1999 09/29/2006 Providing Regulatory Submissions in Electronic Format -- Annual Reports NDAs and ANDAs 08/28/2003 09/29/2006 Q1F: Stability Data Package for Registration Applications for Climactic Zones III and IV 07/01/2004 07/05/2006 Clinical Evaluation of Weight-Control Drugs 09/01/1996 02/15/2007 Anti-Inflammatory and Anti-Rheumatic Drugs (Adults and Children) 04/01/1988 05/29/2008 Labeling OTC Skin Protectant Drug Products 06/04/2003 08/04/2008 Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis 02/11/2004 12/02/2009 Continuous Marketing Applications: Pilot 1 – Reviewable Units for Fast Track Products under PDUFA 10/06/2003 04/09/2010 Continuous Marketing Applications: Pilot 2 – Scientific Feedback and Interactions during Development of Fast Track Products under PDUFA 11/22/2004 04/09/2010 Continuous Marketing Applications: Pilot 2 – Scientific Feedback and Interactions during Development of Fast Track Products under PDUFA; Paperwork Reduction Act Burden Statement 06/17/2003 04/09/2010 Clinical Evaluation of Lipid – Altering Agents 08/14/1998 04/16/2010 Recommendations for Complying with the Pediatric Rule (21 CFR 314.55(a) and 601.27(a)) 12/04/2000 08/09/2010 Labeling Guidance for OTC Topical Drug Products for the Treatment of Vaginal Yeast Infections (Vulvovaginal Candidiasis) 06/01/1998 10/17/2011 Consumer-Directed Broadcast Advertising of Restricted Devices 01/26/2004 08/09/2010 Guideline on Validation of the Limulus Amebocyte Lysate Test 12/01/1987 06/17/2011 Guideline for Validation of Amebocyte Lysate Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products, and Medical Devices 12/01/1987 07/08/2011 Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review 09/01/2009 09/21/2011 Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling 09/12/2006 02/21/2012 In Vivo Drug Metabolism/Drug Interaction Studies - Studn Design, Data Analysis and Recommendations for Dosing and Labeling 11/24/1999 02/21/2012 Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro 04/07/1997 02/21/2012 Cholestyramine Powder In Vitro Bioequivalence 01/15/1993 03/01/2012 Consumer-Directed Broadcast Advertising Questions and Answers 08/09/1999 09/08/2012 Lupus Nephritis Caused By Systemic Lupus Erythematosus--Developing Medical Products for Treatment 06/22/2010 06/27/2012 Manufacturing, Processing, or Holding Active Pharmaceutical Ingredients 04/17/1998 08/07/2013 Powder Blends and Finished Dosage Units - Stratified In-Process Dosage Unit Sampling and Assessment 11/07/2003 08/07/2013 Forms for Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution 05/15/2001 08/07/2013 Disclosing Information Provided to Advisory Committees in Connection With Open Advisory Committee Meetings Related to the Testing or Approval of New Drugs and Convened by CDER, Beginning on January 1, 2000 12/22/1999 08/07/2013 Evaluating Clinical Studies of Antimicrobials in the Division of Anti-Infective Drug Products 02/20/1997 08/07/2013 Empiric Therapy of Febrile Neutropenia; Developing Antimicrobial Drugs for Treatment 07/22/1998 08/07/2013 Lyme Disease—Developing Antimicrobial Drugs for Treatment 07/22/1998 08/07/2013 Secondary Bacterial Infections of Acute Bronchitis—Developing Antimicrobial Drugs for Treatment 07/22/1998 08/07/2013 Streptococcal Pharyngitis and Tonsillitis; Developing Antimicrobial Drugs for Treatment 07/22/1998 08/07/2013 Uncomplicated Urinary Tract Infections; Developing Antimicrobial Drugs for Treatment 07/22/1998 08/07/2013 Uncomplicated Gonorrhea—Developing Antimicrobial Drugs for Treatment 07/22/1998 08/07/2013 Vulvovaginal Candidiasis; Developing Antimicrobial Drugs for Treatment 07/22/1998 08/07/2013 Bacterial Vaginosis; Developing Antimicrobial Drugs for Treatment 07/22/1998 08/07/2013 Acute Bacterial Meningitis; Developing Antimicrobial Drugs for Treatment 07/22/1998 08/07/2013 Acute or Chronic Bacterial Prostatitis; Developing Antimicrobial Drugs for Treatment 07/22/1998 08/07/2013 Developing Antimicrobial Drugs - General Considerations for Clinical Trials 07/22/1998 08/07/2013 Catheter-Related Bloodstream Infections - Developing Antimicrobial Drugs For Treatment 07/22/1998 08/07/2013 Labeling Over-the-Counter Human Drug Products; Updating Labeling in ANDA's 02/22/2001 08/07/2013 Inhalation Drug Products Packaged in Semipermeable Container Closure Systems 07/25/2002 08/07/2013 Listed Drugs, 30-Month Stays, and Approval of ANDAs and 505(b)(2) Applications Under Hatch-Waxman, as Amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003-Questions and Answers
  11/19/2004 08/07/2013 Draft Guidance for Industry on Referencing Discontinued Labeling for Listed Drugs in Abbreviated New Drug Applications 10/26/2000 08/07/2013 Submission of Patent Information for Certain Old Antibiotics 12/03/2008 08/07/2013 Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act 10/01/1999 08/07/2013 Labeling OTC Human Drug Products - Submitting Requests for Exemptions and Deferrals 12/19/2000 10/28/2013 Enforcement Policy During Implementation of Section 503A of the Federal Food, Drug, and Cosmetic Act 11/23/1998 09/22/2008 Providing Electronic Submissions in Electronic Format - ANDAs 06/07/2002 06/11/2008 Providing Electronic Submissions in Electronic Format - NDAs 01/28/1999 06/11/2008 Providing Regulatory Submissions in Electronic Format -- Annual Reports NDAs and ANDAs 08/28/2003 06/11/2008 Phenytoin/Phenytoin Sodium Capsules, Tablets and Suspension In Vivo Bioequivalence and In Vitro Dissolution Testing 12/01/2005 06/05/2014 Development of Parathyroid Hormone for the Prevention and Treatment of Osteoporosis 06/14/2000 04/07/2015 Referencing Discontinued Labeling for Listed Drugs in Abbreviated New Drug Applications 10/26/2000 04/07/2015 Accelerated Approval Products —Submission of Promotional Materials 03/26/1999 05/06/2015 Providing Regulatory Submissions in Electronic Format - Prescription Drug Advertising and Promotional Labeling 01/01/2001 05/06/2015 Comparability Protocols - Protein Drug Products and Biological Products - Chemistry, Manufacturing, and Controls Information  09/05/2003 05/06/2015 Notification to FDA of Issues that May Result in a Prescription Drug or Biological Product Shortage  02/21/2012 05/06/2015 Providing Regulatory Submissions in Electronic Format - General Considerations  10/01/2003 05/06/2015 Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches 12/16/2008 05/28/2015 Using FDA-Approved Patient Labeling in Consumer-Directed Print Advertisements 02/09/2015 08/06/2015 Malaria: Developing Drug and Nonvaccine Biological Products for Treatment and Prophylaxis 06/07/2007 10/13/2015 Vaccinia Virus - Developing Drugs to Mitigate Complications from Smallpox Vaccination 03/09/2004 03/05/2016 Exercise Induced Bronchospasms (EIB) Development of Drugs 02/20/2002 05/10/2016 Classifying Resubmissions in Response to Action Letters 05/14/1998 05/27/2016 Photosafety Testing 05/07/2003 05/27/2016 Interim Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal, Food, Drug and Cosmetic Act 12/04/2013 06/30/2016 Aerosol Steroid Products Safety Information in Prescription Drug Advertising and Promotional Labeling 01/12/1998 10/21/2016 Assessment of Male-Mediated Developmental Risk for Pharmaceuticals 06/12/2015 11/18/2016 Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions; Final 03/18/2002 09/22/2017 Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions; Revision 1 01/27/2004 09/22/2017 M4: Granularity Annex: Final 10/01/2005 10/04/2017 Drug Safety Information – FDA’s Communication to the Public -Draft 03/08/2012 12/04/2017 Drug Safety Information – FDA’s Communication to the Public - Final 03/02/2007 12/04/2017 Formal Meetings Between the FDA and Sponsors or Applicants - Final 05/19/2009 12/27/2017 Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products- Draft 03/10/2015 12/27/2017 Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices 07/02/2009 12/13/2017 Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment (Revised Draft) 05/19/2016 03/26/2018 Sinusitis: Designing Clinical Development Programs of Nonantimicrobial Drugs for Treatment 11/01/2006 04/19/2018 Pediatric Oncology Studies In Response to a Written Request 06/21/2000 04/30/2018 Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants 11/17/2015 06/04/2018 Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms – Recommended Prescribing Information for Health Care Providers and Patient Labeling 11/16/2005 06/07/2018 Statistical Approaches to Evaluate Analytical Similarity Guidance for Industry 09/21/2017 06/21/2018 Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis 07/15/1999 08/22/2018

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.